Sarcoma, Kaposi
A multicentric, malignant neoplastic vascular proliferation characterized by the development of bluish-red cutaneous nodules, usually on the lower extremities, most often on the toes or feet, and slowly increasing in size and number and spreading to more proximal areas. The tumors have endothelium-lined channels and vascular spaces admixed with variably sized aggregates of spindle-shaped cells, and often remain confined to the skin and subcutaneous tissue, but widespread visceral involvement may occur. Kaposi's sarcoma occurs spontaneously in Jewish and Italian males in Europe and the United States. An aggressive variant in young children is endemic in some areas of Africa. A third form occurs in about 0.04% of kidney transplant patients. There is also a high incidence in AIDS patients. (From Dorland, 27th ed & Holland et al., Cancer Medicine, 3d ed, pp2105-7) HHV-8 is the suspected cause.
Drugs by status
Approved for this indication (4)
Phase 4 trials (10)
Phase 2 trials (44)
- didanosine
- abemaciclib
- aldoxorubicin
- lenalidomide
- prednisone
- vismodegib
- incyclinide
- indinavir
- nivolumab
- ixazomib
- pembrolizumab
- l19il2
- lenvatinib
- propranolol
- ipilimumab
- sunitinib
- ephb4-hsa fusion protein
- interleukin-12
- ro 24-7429
- ro4929097
- romiplostim
- sgn-30
- bevacizumab
- talimogene laherparepvec
- everolimus
- bexarotene
- tc99m-tilmanocept
- tin ethyl etiopurpurin
- digoxin
- pacritinib
- +14 more
Phase 1 trials (13)
Other trials (2)
Organizations
Organization Involved with Phase 4 Indications (14)
- Abbott
- Gilead Sciences
- Merck
- Cipla
- National Research Foundation, Singapore
- National Institutes of Health (NIH)
- Medical Research Council
- AIDS Malignancy Consortium
- Sichuan University
- Fudan University
- University of California, San Francisco
- University of Kwa-Zulu Natal
- AIDS Care Research in Africa
- Dermatological Society of South Africa
Organization Involved with Phase 3 Indications (15)
- NeXstar Pharmaceuticals
- GlaxoSmithKline
- Sequus Pharmaceuticals
- Cytran
- AIDS Clinical Trials Group
- National Cancer Institute (NCI)
- National Institute of Allergy and Infectious Diseases (NIAID)
- Albany Medical College
- Eastern Cooperative Oncology Group
- Parirenyatwa Hospital
- University of Zimbabwe
- University of Colorado, Denver
- University of North Carolina at Chapel Hill
- State University of New York, Buffalo
- University of Colorado
Organization Involved with Phase 2 Indications (49)
- Seattle Genetics
- Bristol-Myers Squibb
- Lederle
- Amgen
- Roche
- Schering-Plough
- AstraZeneca
- Agouron
- Pfizer
- Sugen
- Anderson Clinical Research
- Clinical Solutions
- PTC Therapeutics
- Baker Norton Pharmaceuticals
- CytRx
- Otsuka
- The EMMES Corporation
- AIDS Healthcare Foundation
- The Christie NHS Foundation Trust
- Case Western Reserve University
- Cancer Research UK
- University of London
- Cornell University
- Harvard University
- Hoosier Cancer Research Network
- Institut National de la Santé Et de la Recherche Médicale, France
- Instituto Nacional de Enfermedades Respiratorias
- Istituto Superiore di Sanità
- Johns Hopkins University
- Northwestern University
- +19 more
Organization Involved with Phase 1 Indications (11)
Organization Involved with Other Experimental Indications (3)